Phase II Study of Antineoplaston A10 in Patients With Primary Liver Cancer
- Determine the response, tolerance to, and side effects of antineoplaston A10 in
patients with incurable primary liver cancer.
OUTLINE: This is an open label study.
Patients receive gradually increasing doses of antineoplaston A10 by arterial infusion daily
until the final dose level is reached.
Therapy continues for at least 2 months in the absence of unacceptable toxicity and disease
progression. Patients achieving complete response (CR) continue treatment for an additional
2 months after reaching CR.
Tumors are measured every month for the first 2 months, every 2 months for the first year,
and every 3 months for the second year.
PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study.
Masking: Open Label, Primary Purpose: Treatment
Stanislaw R. Burzynski, MD, PhD
Burzynski Research Institute
United States: Federal Government
|Burzynski Clinic||Houston, Texas 77055-6330|